



# Evaluation Form

This interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice

**DATE**

2018/07/04

**LOCATION**

## Demographics

**Physician:** ☐ Yes ☐ No ☐ Other Please specify \_\_\_\_\_

**Type of Practice:** ☐ Full-time ☐ Part-time ☐ Solo ☐ Group ☐ Office ☐ Hospital ☐ Other

## LEARNING OBJECTIVES: **New Horizons in Dyslipidemia Management in Primary Care**

After participating in this activity, I am now better able to:

1. Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently completed clinical trials

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

2. Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardiovascular disease

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

3. Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

4. Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

## LEARNING OBJECTIVES: **Case 2 - LDL-C: How Low Do You Go?**

Upon completion of this case based session, participants will be able to:

1. Apply the recent CCS Dyslipidemia guidelines to clinical practice

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

2. Discuss the importance of lowering LDL-C to target and select the appropriate therapeutic options to achieve guideline recommended targets

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

3. Explain the evidence and safety data for achieving very low LDL-C levels

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

**LEARNING OBJECTIVES: Case 3 - ASCVD with Multiple CV Risk Factors**

Upon completion of this case based session, participants will be able to:

1. Identify patients with ASCVD and with multiple CV risk factors and those who have especially high risk features (eg: PAD)

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

2. Prioritize treatment options in alignment with patient priorities

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

3. Identify circumstances requiring use of statin-add-on therapies to achieve goal

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

4. Review safety and efficacy of PCSK9 inhibitors in specific high risk populations

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

5. Discuss safety and CV risk reduction benefits of very low LDL-C goals

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

**LEARNING OBJECTIVES: Case 4 - Familial Hypercholesterolemia**

1. Review the diagnostic criteria for Familial Hypercholesterolemia

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

2. Apply the newly proposed Canadian definition of Familial Hypercholesterolemia

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

3. Employ evidence-based recommendations to LDL-C targets in this population

|                   |          |         |       |                |
|-------------------|----------|---------|-------|----------------|
| Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
| 1                 | 2        | 3       | 4     | 5              |

## This Program

### Content enhanced my knowledge

Strongly disagree      Neutral      Strongly agree

1      2      3      4      5

### Addressed my most pressing questions

Strongly disagree      Neutral      Strongly agree

1      2      3      4      5

### Promoted improvements or quality in health care

Strongly disagree      Neutral      Strongly agree

1      2      3      4      5

### Was scientifically rigorous and evidence-based

Strongly disagree      Neutral      Strongly agree

1      2      3      4      5

### Provided appropriate and effective opportunities for active learning (ie., case studies, discussion, Q & A, etc)

Strongly disagree      Neutral      Strongly agree

1      2      3      4      5

### Provided an opportunity for interaction with my peers

Strongly disagree      Neutral      Strongly agree

1      2      3      4      5

## Please indicate with CANMEDS roles you felt were addressed during this educational activity.

- ☐ Family Medicine Expert
- ☐ Collaborator
- ☐ Communicator
- ☐ Manager
- ☐ Health Advocate
- ☐ Professional
- ☐ Scholar

### Based on your participation in this program, please select all applicable statement(s):

- ☐ I gained new strategies/skills/information that I can apply to my area of practice.
- ☐ I plan to implement new strategies/skills/information into my practice.
- ☐ I need more information before I can implement new strategies/skills/information into my practice behavior
- ☐ This program will not change my practice, as my current practice is consistent with the information presented.
- ☐ This program will not change my practice, as I do not agree with the information presented.

### What strategies/changes do you plan to implement into your practice?

### What barriers do you see to making a change in your practice?

### Future Topics of Interest / Additional Comment & Suggestions

**Thank you for your feedback!**